September 2018

New Indications

Dabrafenib (Tafinlar) in combination with trametinib is now indicated for the adjuvant treatment of melanoma with a BRAF V600 mutation and involvement of the lymph node(s), following complete resection.

Denosumab (rch) (Xgeva) is now indicated for prevention of skeletal related events associated with multiple myeloma.

Nivolumab (Opdivo) in combination with ipilimumab is now indicated for the treatment of: unresectable melanoma; intermediate/poor risk, previously untreated advanced renal cell carcinoma.

Osimertinib (mesilate) (Tagrisso) is now indicated for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) tumours with activating epidermal growth factor receptor (EGFR) mutations.

Terlipressin (Lucassin) is now indicated for treatment of bleeding oesophageal varices.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au